AUTHORS
Sandhya Panch, MD, Irina Murakhovskaya, MD2, Yasutaka Ueda, MD, PhD3, Arpad Illes, MD4, Darla Liles, MD5, Michal Witkowski6, Maria Eva Mingot Sr, PhD7, Doug Schlichting, PhD8, Kristen Sweet, PhD9, Michael Zelasky10, Sheryl Pease, MBA11, Cathye Shu12, Bruno Fattizzo, MD13
AFFILIATIONS
1 Clinical Research Division, Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
2 Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, United States
3 The University of Osaka, Suita, Osaka, Japan
4 Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
5 ECU Health Medical Center, Greenville, North Carolina, United States
6 Copernicus Memorial Hospital, Lodz, Poland
7 Hospital Universitario Virgen del Rocío, Institudo de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Seville, Spain
8 Johnson & Johnson, Spring House, Pennsylvania, United States
9 Johnson & Johnson, Spring House, Pennsylvania, United States
10 Johnson & Johnson, Spring House, Pennsylvania, United States
11 Johnson & Johnson, Raritan, New Jersey, United States
12 Johnson & Johnson, Spring House, Pennsylvania, United States
13 Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy, Hematology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
ABSTRACT
Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening disease characterized by IgG autoantibody-mediated premature destruction of red blood cells. Fatigue, often debilitating, is the primary symptom for many individuals living with wAIHA and is associated with substantial impacts across multiple aspects of health-related quality of life. Nipocalimab is an immunoselective neonatal Fc receptor blocker that reduces circulating IgG levels, including IgG autoantibodies. In the 24-week double-blind phase 2/3 ENERGY trial, nipocalimab demonstrated durable hemoglobin response and improvement in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue in participants with wAIHA (Fattizzo B, et al. HemaSphere. 2026;10(S1):466). Here we describe patient-reported health-related quality of life outcomes during the double-blind period of the ENERGY trial.
Methods: ENERGY (ClinicalTrials.gov identifier: NCT04119050) included adults with wAIHA randomized 1:1:1 to IV nipocalimab 30 mg/kg q4w (n=38), 15 mg/kg q2w (n=38), or placebo (n=39) during the 24-week double-blind period. Fatigue was quantified by the FACIT-Fatigue (key secondary endpoint), a validated patient-reported outcome measure (Pease S, et al. J Patient Rep Outcomes. 2025;9(1):97), and single item Patient Global Impressions of Severity and Change (PGIS and PGIC) measures for fatigue. General health-related quality of life was measured by the Medical Outcomes Study Short Form 36-Item Version 2 Acute (SF-36v2 Acute) and EuroQol 5-dimension visual analogue scale (EQ-5D VAS).
Results: FACIT-Fatigue total scores improved by W2 in both nipocalimab arms and the nipocalimab 30 mg/kg q4w group sustained improvement over time throughout the double-blind period to W24. Additionally, the PGIS and PGIC anchor measure results showed greater patient-reported improvement in fatigue versus placebo. Both nipocalimab dose groups reported greater mean (SD) improvements from baseline to Week 24 in SF-36v2 Acute physical and mental component scores versus placebo: physical, 1.05 (6.42) for 30 mg/kg q4w and 1.16 (4.66) for 15 mg/kg q2w versus -0.68 (3.94); mental, 2.15 (9.07) and 0.73 (7.48) versus -0.12 (5.62). Additionally, the nipocalimab groups reported better scores in all eight domains of the SF-36v2 Acute compared to placebo. Patient-reported general health status measured by EQ-5D VAS mean (SD) change from baseline to W24 was 6.0 (16.13), 3.1 (10.81) and 1.8 (7.38) for the 30 mg/kg q4w, 15 mg/kg q2w and placebo groups, respectively.
Conclusion: Nipocalimab treatment was associated with greater improvements in patient-reported health-related quality of life compared with placebo at W24, including improvements in overall fatigue, as well as in physical and mental component scores. These findings suggest that nipocalimab may provide patient-perceived benefits in addition to its clinical effects, supporting further confirmation of its impact on health-related quality of life.
DISCLOSURES
Sandhya Panch, MD: Novartis - Honoraria; Sobi - Honoraria; Sanofi - Honoraria; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Research Funding; Incyte, Novartis, Uoro Med., Sanofi, SOBI, and Takeda - Research Funding; Amgen, Argenyx, J&J, Novartis, Sanofi, Sobi, and Recordati - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)